Clinical Studies

Clinical studies are critical to help deliver innovative medicines to people with cancer. These studies ensure that an investigational medicine is effective and safe. We are grateful to the patients, healthy volunteers, families, hospitals and clinics that participate in our clinical studies and help make progress possible.

For more information, follow the links below to the study listings on Medical professionals may also email us at for specific questions related to our clinical studies.




Our clinical studies
  • Ripretinib

    Disease Phase Study Focus More Info
    GIST – 2nd line Phase 3 Pivotal Study A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib (intrigue)
    GIST Phase 1 Expansion Study A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies


  • Vimseltinib

    Disease Phase Study Focus More Info
    Malignant solid tumors and tenosynovial giant cell tumor (TGCT) Phase 1/2 Study A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
    Tenosynovial giant cell tumor (TGCT) Phase 3 A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)


  • Rebastinib

    Disease Phase Study Focus More Info

    Solid Tumors in Combination with Paclitaxel
    (includes endometrial, ovarian and breast cancers)

    Phase 1b/2 Study A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors


  • DCC-3116

    Disease Phase Study Focus More Info
    Advanced or metastatic solid tumors with RAS or RAF mutations Phase 1 A Phase 1, First-in-Human Study of DCC-3116 as a Single Agent and in Combination With Trametinib in Patients With Advanced or Metastatic Solid Tumors With RAS or RAF Mutations